Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

McKesson forecast fiscal 2026 profit largely above estimates on Thursday and said it is planning to spin off its medical-surgical solutions unit into an independent company to focus on its core drug ...

In the wake of mass restructuring efforts across the Department of Health and Human Services, the FDA has missed yet another ...

Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year ...

Vaccine maker Novavax stock jumped double digits on Thursday after the company reported its quarterly sales had more than ...

Senior leaders at the FDA began pushing Moderna and Pfizer to file for full, formal approval of their COVID vaccines for ...

Merck Animal Health, a unit of Merck , said on Thursday it would invest $895 million to expand its manufacturing facility in ...

Officials in sixteen states and the District of Columbia sued in response, leading to Tuesday’s order from U.S. District ...

A blanket requirement for placebo-controlled trials threatens research ethics and vaccine access, it’s being argued.

Yes, according to leading vaccine physician Paul Offit, who denounced the new placebo-controlled trial requirements for ...

The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.

The FDA has already delayed the approval of Novavax’s updated Covid vaccine, requiring the company to carry out a new ...